Get the Daily Brief
Latest Biotech News
GSK and Hengrui Ink $12.5 Billion Collaboration for Respiratory and Oncology Assets
GSK plc expanded its respiratory and immunology portfolio through a strategic partnership with Hengrui Pharmaceuticals. The deal includes a $500 million upfront payment for an exclusive global...
GeneDx Reports Surge in Genome and Exome Testing Revenues, Boosts 2025 Guidance
Gaithersburg-based genetic diagnostics company GeneDx reported a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, driven largely by whole-exome and whole-genome testing which...
Apellis’ Empaveli Gains FDA Approval for Rare Kidney Diseases
Apellis Pharmaceuticals received FDA approval for an expanded indication of its complement 3 (C3) inhibitor pegcetacoplan, marketed as Empaveli, for two rare kidney disorders: complement 3...
Boehringer and Re-Vana Partner in Eye Health with Potential $1B Deal
Boehringer Ingelheim has expanded its ophthalmology portfolio by entering a collaboration with Re-Vana Therapeutics to develop extended-release ocular therapies. The potential partnership, valued...
AI and Computational Innovations Propel Biotech Research and Diagnostics
Advances in AI and computational technologies are reshaping biotech R&D and diagnostics. NIH researchers unveiled GeneAgent, an LLM-powered gene-set analysis tool that autonomously verifies...
Bayer, Bristol Myers, and Bain Drive Pharma Portfolio Reshaping and Financing
Bayer aims to revive growth through new drug launches as key products like Xarelto and Eylea plateau. Bristol Myers Squibb is realigning its pipeline by transferring five immunology assets,...
Sarepta's Duchenne gene therapy shipment reversal
The FDA has reversed its recent halt on Sarepta Therapeutics’ gene therapy Elevidys for ambulatory patients with Duchenne muscular dystrophy (DMD) following an investigation that concluded an...
Novo Nordisk cuts guidance amid leadership change
Novo Nordisk dramatically reduced its 2025 sales growth forecast to 8%-14% from a previous 13%-21%, citing ongoing challenges from lower sales of popular GLP-1 drugs due to knockoff competition....
Merck initiates $3B cost-cutting to refocus portfolio
Merck announced a sweeping initiative to save $3 billion annually by 2027, redirecting funds from mature products to support new launches and its experimental pipeline. The program involves...
Celcuity's breast cancer drug charts phase III success
Minneapolis biotech Celcuity reported positive phase III results for its breast cancer therapy gedatolisib, which demonstrated significant progression-free survival benefits in hormone...
GSK and Hengrui's $12.5B drug collaboration
GlaxoSmithKline inked a significant licensing deal with China’s Hengrui Pharmaceuticals for up to $12.5 billion, gaining rights to 12 drug assets including HRS-9821, a PDE3/4 inhibitor targeting...
GeneDx reports strong growth and raised revenue outlook
Genetic testing firm GeneDx posted a 49% increase in Q2 revenue driven by higher volumes of whole-exome and whole-genome sequencing tests, marking its fourth consecutive profitable quarter. The...
FDA expands approval for Apellis’ rare kidney disease drug
Apellis Pharmaceuticals won FDA approval for an expanded indication of its complement pathway drug pegcetacoplan (Empaveli), making it the second approved treatment for complement 3 glomerulopathy...
AI and computational advances boost biotech innovation
Recent advances in AI applications are reshaping biotech research and development. Researchers at NIH introduced GeneAgent, an AI agent that improves accuracy of gene-set analysis by reducing...
Bayer aims for growth with new product launches
Bayer outlined its strategy to return to growth leveraging new product launches as revenues from established drugs like Xarelto and Eylea plateau. The German pharma aims to replenish its portfolio...
FDA Clears Sarepta to Resume Duchenne Gene Therapy Shipments
The FDA reversed its earlier decision and authorized Sarepta Therapeutics to resume shipments of Elevidys, its gene therapy for ambulatory Duchenne muscular dystrophy (DMD) patients, after...
Merck Launches $3 Billion Cost-Cutting Plan to Bolster Pipeline
Merck & Co. announced a sweeping multiyear initiative aiming to cut $3 billion in annual costs by 2027, reallocating resources from mature assets to support newly launched and pipeline drugs. The...
GSK and Hengrui Pharma Ink Up to $12.5 Billion Deal for Respiratory and Oncology Assets
GSK partnered with Jiangsu Hengrui Pharmaceuticals in a licensing deal valued at up to $12.5 billion, centered on HRS-9821, a PDE3/4 inhibitor in phase I for chronic obstructive pulmonary disease...
GeneDx Reports Robust Growth with Strength in Genome and Exome Testing
Genetic diagnostics firm GeneDx posted a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, fueled primarily by a 69% surge in whole-exome and whole-genome testing revenues, which...
Celcuity Breast Cancer Drug Surges on Positive Phase III Results
Minneapolis-based Celcuity’s experimental breast cancer therapy gedatolisib demonstrated significant efficacy in a phase III trial, achieving primary endpoints and substantially reducing...